Company intelligence / Profile preview
M's Science Corporation
Kobe, Japanm-sci.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has developed two programs that have progressed to clinical trial stages with satisfactory results: a sigma-1 receptor agonist for CNS diseases and an attenuated live herpes simplex virus for solid tumors (which was sold in 2010)[2]
- Therapeutic areas
- OphthalmologyOncologyNeurology
- Modalities
- Small molecules (sigma-1 receptor agonists)Attenuated live herpes simplex virus (previously)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on M's Science Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M's Science Corporation.